Remdesivir: Currently in phase 3 studies.
Remdesivir (RDV,GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp).
Dr. George Martin: My understanding is that there is a fast track phase 3 trial of 1,000 patients here and in China. This is a therapeutic “game changer” based on its success when used in compassionate use outcomes in a limited number of people. It has a therapeutic window when used in the first 5-10 days before the cytokine storm sets in. Currently IL-6 inhibitor are being studied to attenuate the inflammatory response i.e. “cytokine storm” caused by the immune response in the lung to COVID19
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04302766
Contact: Sandi K. Parriot, 301-619-6824, email@example.com
Ages Eligible for Study: Child, Adult, Older Adult
Sexes Eligible for study: All
- DoD-affiliated personnel (including active and reserve component service members, US civilian employees, contractors, other US personnel, and dependents of any age, as well as allied military forces and local nationals) who have been granted access to the medical facility
- Have a COVID-19 diagnosis
- Available for clinical follow-up for duration of the treatment and follow-up period
• Unable or unwilling to meet the requirements of the protocol
Sponsors/Collaborators: U.S. Army Medical Research and Development Command